Progress Toward Novel Treatments for Chronic Kidney Disease
- 30 September 2010
- journal article
- review article
- Published by Elsevier BV in Journal of Renal Nutrition
- Vol. 20 (5), S122-S126
- https://doi.org/10.1053/j.jrn.2010.06.013
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Pirfenidone Is Renoprotective in Diabetic Kidney DiseaseJournal of the American Society of Nephrology, 2009
- Novel therapies of diabetic nephropathyCurrent Opinion in Nephrology and Hypertension, 2009
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designNephrology Dialysis Transplantation, 2009
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialThe Lancet, 2008
- Aliskiren Combined with Losartan in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2008
- Effects of sulodexide in patients with type 2 diabetes and persistent albuminuriaNephrology Dialysis Transplantation, 2008
- Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental GlomerulosclerosisClinical Journal of the American Society of Nephrology, 2007
- Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye DiseaseClinical Journal of the American Society of Nephrology, 2007
- Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive PatientsCirculation, 2005